What is the Orladeyo patent infringement lawsuit about?
A patent infringement lawsuit has been filed against BioCryst Pharmaceuticals regarding its drug Orladeyo (berotralstat) [1]. The lawsuit alleges that BioCryst infringed on a patent held by the University of Rochester [1].
Who is involved in the Orladeyo patent dispute?
The University of Rochester is the plaintiff in the patent infringement lawsuit, while BioCryst Pharmaceuticals is the defendant [1].
When was the Orladeyo patent infringement lawsuit filed?
The lawsuit was filed on January 12, 2024, in the U.S. District Court for the District of Delaware [1].
What patent is allegedly being infringed?
The patent in question is U.S. Patent No. 10,024,072 [1]. This patent covers a method of treating hereditary angioedema (HAE) [1].
What does Orladeyo treat?
Orladeyo is approved to treat patients 12 years and older with hereditary angioedema (HAE) [2].
What is the basis of the University of Rochester's claim?
The University of Rochester claims that Orladeyo's method of use infringes on its patented method for treating HAE [1].
What are the potential implications of this lawsuit for BioCryst?
If the University of Rochester prevails, it could lead to an injunction that would halt BioCryst from selling Orladeyo, or it could result in significant financial damages [1].
What is the history of the patented technology?
The patent originated from research conducted by Dr. Anne Hammes at the University of Rochester Medical Center, focusing on a specific enzymatic pathway related to HAE [1].
Where can I find more information on drug patents and litigation?
Information on drug patents and related litigation can often be found on resources like DrugPatentWatch.com [3].
---
Sources
[1] https://www.biocryst.com/investors/sec-filings/content/000119312524012744/000119312524012744.pdf
[2] https://www.biocryst.com/patients/orladeyo/
[3] https://www.drugpatentwatch.com/